Avalon Investment & Advisory’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | $21.3M | Sell |
62,151
-1,543
| -2% | -$520K | 0.58% | 49 |
|
|
2022
Q4 | $23.3M | Buy |
+63,694
| New | +$22.6M | 0.66% | 45 |
|
|
2021
Q2 | – | Sell |
-4,500
| Closed | -$841K | – | 362 |
|
|
2021
Q1 | $841K | Sell |
4,500
-1,800
| -29% | -$352K | 0.02% | 252 |
|
|
2020
Q4 | $1.06M | Sell |
6,300
-726
| -10% | -$108K | 0.02% | 240 |
|
|
2020
Q3 | $1.04M | Sell |
7,026
-153
| -2% | -$23.7K | 0.02% | 217 |
|
|
2020
Q2 | $1.18M | Sell |
7,179
-499
| -6% | -$76.6K | 0.03% | 207 |
|
|
2020
Q1 | $1.06M | Sell |
7,678
-4,564
| -37% | -$627K | 0.03% | 217 |
|
|
2019
Q4 | $1.61M | Sell |
12,242
-25
| -0.2% | -$2.9K | 0.03% | 216 |
|
|
2019
Q3 | $1.37M | Sell |
12,267
-6,973
| -36% | -$776K | 0.03% | 225 |
|
|
2019
Q2 | $2.13M | Sell |
19,240
-104,696
| -84% | -$12.3M | 0.05% | 207 |
|
|
2019
Q1 | $16.1M | Sell |
123,936
-7,172
| -5% | -$872K | 0.37% | 87 |
|
|
2018
Q4 | $15.2M | Buy |
131,108
+32,068
| +32% | +$3.58M | 0.39% | 72 |
|
|
2018
Q3 | $10.6M | Sell |
99,040
-164,897
| -62% | -$16.5M | 0.3% | 122 |
|
|
2018
Q2 | $22.5M | Sell |
263,937
-9,978
| -4% | -$820K | 0.67% | 51 |
|
|
2018
Q1 | $21.2M | Buy |
273,915
+965
| +0.4% | +$77.7K | 0.66% | 54 |
|
|
2017
Q4 | $23.1M | Buy |
272,950
+28,308
| +12% | +$2.41M | 0.72% | 39 |
|
|
2017
Q3 | $20.9M | Buy |
244,642
+1,716
| +0.7% | +$141K | 0.67% | 42 |
|
|
2017
Q2 | $20M | Sell |
242,926
-25,969
| -10% | -$2.12M | 0.66% | 43 |
|
|
2017
Q1 | $22.6M | Buy |
268,895
+90,919
| +51% | +$7.28M | 0.78% | 39 |
|
|
2016
Q4 | $13.1M | Buy |
+177,976
| New | +$13.3M | 0.47% | 72 |
|
|
2016
Q2 | – | Sell |
-3,142
| Closed | -$226K | – | 287 |
|
|
2016
Q1 | $226K | Sell |
3,142
-214,522
| -99% | -$16.2M | 0.01% | 241 |
|
|
2015
Q4 | $18.3M | Sell |
217,664
-138,873
| -39% | -$11.5M | 0.79% | 43 |
|
|
2015
Q3 | $29.8M | Sell |
356,537
-154,529
| -30% | -$13M | 1.32% | 17 |
|
|
2015
Q2 | $42.7M | Buy |
511,066
+3,259
| +0.6% | +$248K | 1.84% | 7 |
|
|
2015
Q1 | $36.9M | Buy |
507,807
+11,154
| +2% | +$794K | 1.61% | 9 |
|
|
2014
Q4 | $34.3M | Buy |
496,653
+24,415
| +5% | +$1.65M | 1.56% | 11 |
|
|
2014
Q3 | $30.6M | Buy |
472,238
+906
| +0.2% | +$57.4K | 1.55% | 15 |
|
|
2014
Q2 | $29.3M | Buy |
471,332
+34,607
| +8% | +$2.06M | 1.48% | 18 |
|
|
2014
Q1 | $25.7M | Buy |
436,725
+141,275
| +48% | +$7.88M | 1.42% | 18 |
|
|
2013
Q4 | $15.1M | Buy |
295,450
+2,119
| +0.7% | +$106K | 0.84% | 38 |
|
|
2013
Q3 | $14.8M | Sell |
293,331
-2,020
| -0.7% | -$106K | 0.95% | 29 |
|
|
2013
Q2 | $14.5M | Buy |
+295,351
| New | +$16.1M | 0.87% | 33 |
|
Other funds holding LLY
Avalon Investment & Advisory's LLY Position: Q1 2023 in Review
Avalon Investment & Advisory reduced its Eli Lilly (LLY) stake by 2.4% in Q1 2023, selling an estimated $520K and leaving 62,151 shares worth $21.3M. The position accounts for 0.58% of the portfolio, ranked #49.
Avalon Investment & Advisory first reported a position in LLY in Q2 2013 and has held it in 32 quarters since. The position peaked at $42.7M in Q2 2015. 2,614 funds tracked by Wall St. Rank hold LLY as of Q1 2023.
- Avalon Investment & Advisory held 62,151 shares of Eli Lilly worth $21.3M as of Q1 2023.
- Avalon Investment & Advisory sold 1,543 Eli Lilly shares in Q1 2023, an estimated $520K.
- Eli Lilly made up 0.58% of Avalon Investment & Advisory's portfolio in Q1 2023, its #49 holding.
- Avalon Investment & Advisory first reported a position in Eli Lilly in Q2 2013 and has held it in 32 quarters since.
- Avalon Investment & Advisory's Eli Lilly position peaked at $42.7M in Q2 2015.
- 2,614 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2023.
Based on Avalon Investment & Advisory's 13F filing for Q1 2023, filed 15 May 2023.